Systemic treatment for metastatic prostate cancer
نویسندگان
چکیده
منابع مشابه
Systemic treatment for prostate cancer.
Prostate cancer is a leading cause of cancer mortality in adult men. The majority of patients have subclinical systemic disease at diagnosis and will eventually require systemic therapy for palliation of symptoms. Recent development of new hormonal treatment options (e.g., gonadotropin-releasing hormone analogues and estramustine) has yet to demonstrate potential for improving the therapeutic i...
متن کاملTreatment of Metastatic Prostate Cancer
The traditional definition of “metastatic” prostate cancer refers to disease stage and traditionally has included only patients with widespread osteoblastic or soft tissue metastases (clinical or pathologic stage Tany Nany M1, D2); it does not take into account the pathogenicity of the cancer or the risk of metastasis. Current evidence indicates that this definition should be broadened to inclu...
متن کاملHormonal and Chemotherapeutic Systemic Therapy for Metastatic Prostate Cancer.
BACKGROUND: Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer death in men in the United States. It is estimated that over 300,000 men will have been diagnosed with prostate cancer in 1996, and more than 40,000 will have died of this disease. METHODS: The authors combined their experience with a review of the literature on management of this disease ...
متن کاملSystemic Medical Treatment in Men with Metastatic Castration-Resistant Prostate Cancer: Recommendations for Daily Routine.
The approval or clinical evaluation of several new agents - cabazitaxel, abiraterone acetate, enzalutamide, sipuleucel-T, and radium-223 - has significantly changed the management of patients with metastatic castration-resistant prostate cancer (mCRPC) prior to or after docetaxel-based chemotherapy. All of these agents have resulted in a significant survival benefit as compared to their control...
متن کاملTreatment of metastatic prostate cancer after STAMPEDE
tau.amegroups.com © Translational Andrology and Urology. All rights reserved. Over decades, long-term hormone therapy has been considered as the standard of care (SOC) for men with advanced prostate cancer. The problem is that several months after the commencement of treatment, tumors become castration-resistant and virtually all patients show disease progression. In 2004, two randomized Phase ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Asian Journal of Urology
سال: 2019
ISSN: 2214-3882
DOI: 10.1016/j.ajur.2019.02.002